Abstract
A ‘global’ model of hERG K+ channel was built to satisfy three basic criteria for QSAR models in drug discovery: (1) assessment of the applicability domain, (2) assuring that model decisions can be interpreted by medicinal chemists and (3) assessment of model performance after the model was built. A combination of D-optimal onion design and hierarchical partial least squares modelling was applied to construct a global model of hERG blockade in order to maximize the applicability domain of the model and to enhance its interpretability. Additionally, easily interpretable hERG specific fragment-based descriptors were developed. Model performance was monitored, throughout a time period of 15 months, after model implementation. It was found that after this time duration a greater proportion of molecules were outside the model’s applicability domain and that these compounds had a markedly higher average prediction error than those from molecules within the model’s applicability domain. The model’s predictive performance deteriorated within 4 months after building, illustrating the necessity of regular updating of global models within a drug discovery environment.
Similar content being viewed by others
References
Brown AM (2004) Cell Calcium 35:543
Finlayson K, Witchel HJ, McCulloch J, Sharkey J (2004) Eur J Pharmacol 500:129
Guth BD, Germeyer S, Kolb W, Markert M (2004) J Pharmacol Toxicol Meth 49:159
Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F (2005) Med Res Rev 25:133
Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG (2003) Cardiovasc Res 58:32
Sanguinetti MCM, John S (2005) Trends Pharmacol Sci 26:119
Hammond TPC (2005) Toxicol Appl Pharmacol 207:446
Aronov AM (2005) Drug Discov Today 10:149
Cavalli A, Poluzzi E, De Ponti F, Recanatini M (2002) J Med Chem 45:3844
Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA (2002) J Pharmacol Exp Ther 301:427
Pearlstein RA, Vaz RJ, Kang J, Chen X-L, Preobrazhenskaya M, Shchekotikhin AE, Korolev AM, Lysenkova LN, Miroshnikova OV, Hendrix J, Rampe D (2003) Bioorg Med Chem Lett 13:1835
Aronov AM, Goldman BB (2004) Bioorg Med Chem 12:2315
Osterberg F, Aqvist J (2005) FEBS Lett 579:2944
Rajamani R, Tounge BA, Li J, Reynolds CH (2005) Bioorg Med Chem Lett 15:1741
Bains W, Basman A, White C (2004) Prog Biophys Mol Biol 86:205
Bains W, Basman A, White C (2004) Prog Biophys Mol Biol 86:233
Cianchetta G, Li Y, Kang J, Rampe D, Fravolini A, Cruciani G, Vaz RJ (2005) Bioorg Med Chem Lett 15:3642
Keseru GM (2003) Bioorg Med Chem Lett 13:2775
Olivier Roche GT, Zuegge J, Pflimlin P, Alanine A, Schneider G (2002) ChemBioChem 3:455
Roche O, Trube G, Zuegge J, Pflimlin P, Alanine A, Schneider G (2002) Chembiochem 3:455
Tobita M, Nishikawa T, Nagashima R (2005) Bioorg Med Chem Lett 15:2890
Eriksson L, Johansson E, Lindgren F, Sjostrom M, Wold S (2002) J Comput Aided Mol Des 16:711
Kiralj R, Ferreira MMC (2003) J Mol Graph 21:448
Purdy R (1996) Environ Health Perspect 104:1085
Gute BD, Basak SC (1997) SAR QSAR Environ Res 7:117
Eriksson L, Arnhold T, Beck B, Fox T, Johansson E, Kriegl JM (2004) J Chemom 18:188
Song M, Clark M (2006) J Chem Inf Model 46:392
Fenichel, R.R., http://www.fenichel.net/pages/Professional/subpages/QT/Tables/pbydrug.htm
Bridgland-Taylor MH, Hargreaves AC, Easter A, Orme A, Henthorn DC, Ding M, Davis AM, Small BG, Heapy CG, Abi-Gerges N (2006) J Pharmacol Toxicol Meth 54:189
Bett G, Rasmusson R (2003) Cell Biochem Biophys 39:183
Milnes J, Crociani O, Arcangeli A, Hancox J, Witchel H (2003) Br J Pharmacol 139:887
Sanguinetti MC, Mitcheson JS (2005) Trends Pharmacol Sci 26:124
Friedrichs GS, Patmore L, Bass A (2005) J Pharmacol Toxicol Meth 52:11
Lawrence CL, Pollard CE, Hammond TG, Valentin J-P (2005) J Pharmacol Toxicol Meth 52:59
Schroeder K, Neagle B, Trezise DJ, Worley J (2003) J Biomol Screen 8:50
Selma is an in-house AstraZeneca program. For further information contact T. Olsson, V.S., Synthesis and Structure Administration (SaSA), Astrazeneca R&D Mölndal, Sweden
Bruneau P (2001) J Chem Inf Model 41:1605
Cruciani G, Pastor M, Guba W (2000) Eur J Pharm Sci 11:S39
Glen RC (1994) J Comput Aided Mol Des 8:457
Kier LB, Hall LH, (1986) Research Studies Press. John Wiley and Sons, Letchwort
Gasteiger J, Marselli M (1980) Tetrahedron 36:3219
Cruciani C, Crivori P, Carrupt PA, Testa B (2000) Theochem-J Mol Struct 503:17
Roberts G, Myatt GJ, Johnson WP, Cross KP, Blower PE (2000) J Chem Inf Comp Sci 40:1302
www.daylight.com (Subgraph matching is part of the SMARTS Toolkit)
Wold S (1978) Technometrics 20:397
van der Voet H (1994) Chemometr Intell Lab Syst 25:323
Hawkins DM, Basak SC, Mills D (2003) J Chem Inf Model 43:579
Eriksson L, Johansson E, Kettaneh-Wold N, Wold S (2001) Multivariate and megavariate data analysis - principles and applications. Umetrics Academy, pp 65–67
Acknowledgements
The authors thank the following from Safety Pharmacology, Astrazeneca Pharmaceuticals, Department of Safety Assessment, Alderley Park, Macclesfield, Cheshire SKN 4TG, U.K.: B.G. Small, M.H. Bridgeland-Taylor, A.J. Woods and A. Harmer for generating the IonWorks™ HT Data that form the basis of this work and C.E. Pollard for discussions around the biological aspects of this manuscripts
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gavaghan, C.L., Arnby, C.H., Blomberg, N. et al. Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data. J Comput Aided Mol Des 21, 189–206 (2007). https://doi.org/10.1007/s10822-006-9095-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10822-006-9095-6